The Department of Pharmaceuticals (DoP) has given the green light for Rs. 243 crore in funding to establish Centers of Excellence (CoEs) within the National Institutes of Pharmaceutical Education and Research (NIPERs) for the upcoming fiscal year 2024-25.
This initiative is part of the broader Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, launched last year to boost research and development (R&D) and innovation across pharmaceuticals, medical devices, and animal health sectors.
The decision came after the inaugural steering committee meeting chaired by the DoP secretary, which reviewed plans to establish CoEs at NIPERs. These Centers of Excellence are a critical component (Component A) of the PRIP scheme, with the committee approving proposals from all NIPERs and setting a total budget of Rs. 700 crore over the next five years.
“Out of this allocated amount, Rs. 243 crore has been sanctioned for the fiscal year 2024-25,” stated the DoP.
Under the PRIP scheme, which has an overall budget of Rs. 5,000 crore, Component A focuses on strengthening research infrastructure through seven CoEs at different NIPERs, specializing in areas such as antiviral and antibacterial drug discovery, medical devices, bulk drugs, and more.
The scheme aims to enhance specific research capabilities in these priority areas within a defined timeframe, fostering collaboration between industry and academia. It is designed not only to bolster research infrastructure but also to cultivate a skilled workforce and promote innovation in the Pharma-MedTech sectors.
According to the DoP, the initiative is crucial as India’s pharmaceutical industry has traditionally excelled in generic drugs but now seeks to expand its footprint in new areas of potential growth. This shift is highlighted by the identification of six priority research areas, termed “moon-shot areas,” aimed at propelling the industry forward.
Under Component B of the PRIP scheme, financial assistance will support research in these priority areas through collaboration between established pharmaceutical companies, government institutes, and national universities. This collaborative effort aims to leverage existing research infrastructure while providing training opportunities to students and scientists.
The PRIP scheme marks a strategic step towards advancing India’s position in pharmaceutical innovation, addressing the need for increased R&D investment and fostering future growth in the sector.